Novel methylation gene panel in adjacent normal tissues predicts poor prognosis of colorectal cancer in Taiwan

Table 3 Relationship between the number of hypermethylated genes and 5-year overall survival of colorectal cancer patients, n (%)

	Normal tissues						Tumor tissues
	No. of subjects	No. of cases	Crude		Adjusted		No. of subjects	No. of cases	Crude		Adjusted
			HR	95%CI	HR	95%CI			HR	95%CI	HR	95%CI
NO. of methylated genes
0	9	1 (11.11)	1.00	Referent	1.00	Referent	3	1 (33.33)	1.00	Referent	1.00	Referent
1	34	7 (20.59)	1.52	0.19-12.4	1.19	0.14-10.1	7	0 (0)	N/A	N/A	N/A	N/A
2	42	8 (19.05)	1.76	0.22-14.1	0.89	0.10-8.40	28	7 (25)	0.95	0.12-7.72	0.73	0.08-6.55
3	21	4 (19.05)	1.79	0.20-16.0	1.41	0.15-13.2	39	6 (15.38)	0.66	0.08-5.47	0.59	0.07-5.2
4	11	2 (18.18)	2.11	0.19-23.3	1.40	0.10-18.8	23	6 (26.09)	1.24	0.15-10.3	1.16	0.13-10.2
5	3	1 (33.33)	4.89	0.30-78.8	4.91	0.29-83.4	17	3 (17.65)	0.84	0.09-8.06	0.60	0.05-7.13
6	0	0 (0)	N/A	N/A	N/A	N/A	3	0 (0)	N/A	N/A	N/A	N/A
P value1				0.33		0.40				0.59		0.64
≥ 3 of genes2	35	7 (20.0)	1.31	0.54-3.18	1.50	0.59-3.81	82	15 (18.3)	1.13	0.48-2.66	1.21	0.47-3.10

Adjusted for gender, age at surgery (continuous), adjuvant chemotherapy, histological grade and tumor location.

¹P for trend.

²Including CDKN2A, hMLH1, MGMT, CSF2, DIS3L2, and OAF. CI: Confidence interval; HR: Hazard ratio; N/A: Not applicable.